Amarin (AMRN) 10-Q2015 Q1 Quarterly report

Filed: 8 May 15, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: absent, alter, alteration, antioxidant, arriving, Asia, assist, assistance, BCF, billion, Capsugel, Catalent, China, commensurate, country, CRL, DCS, dealing, disorder, Eddingpharm, element, enhancement, entirety, equating, escalating, exemption, external, fifteen, flat, formulary, fulfill, futility, hand, Healy, Hong, Imputation, indemnification, ineffective, inherent, insufficient, interruption, intrinsic, Kong, Macao, Macau, Mainland, mention, modestly, multiplied, Offshore, overcome, overly, partnership, Prasco, prejudice, ranging, redesignated, redesignation, register, registered, renew, representation, robust, Simplifying, slight, slightly, Sofinnova, speech, stoppage, sublicense, subscription, surrogate, Taiwan, Territory, thousand, timeframe, truthful, twelfth, unblinded, unblinding, uncured, undelivered, unrecognized, vague, vendor, Venture, VII, VSOE, widely, winter

Removed: add, affiliate, albeit, andAmarin, andSiegel, appealed, appealing, arbitration, arise, assigned, begin, bound, captionedAmarin, captionedBove, captionedSteven, certainty, CHD, Civ, clinician, closed, Columbia, concomitant, concomitantly, Concurrent, contending, CT, deferral, degradation, diligence, division, DMEP, Endocrinology, enjoining, equipment, forecast, forfeited, Groton, headcount, hedge, hypothetical, Ill, infringed, input, invested, invoiced, isolation, Jersey, John, litigate, Metabolism, Northern, noted, notification, notional, Nov, ODE, Ohio, originally, outlining, PDUFA, pharmacological, plant, predicted, prevailing, procedural, protein, putative, reacquiring, reconsideration, Reddy, released, relevance, residual, residually, resold, resource, Roxane, RSU, sensitive, Sklar, spend, spending, stocked, stocking, substantiate, suspended, unrealized, uphold, User, Watson, worthy, wrongfully

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

AMRN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

STATEMENT PURSUANT TO 18 U.S.C. § 1350

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), John F. Thero, President and Chief Executive Officer (Principal Executive Officer) of Amarin Corporation plc (the “Company”) and Michael J. Farrell, Vice President, Finance (Principal Financial Officer) of the Company, each hereby certifies that, to the best of his knowledge:

(1)	The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2015, to which this Certification is attached as Exhibit 32.1 (the “Quarterly Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the end of such year.


						/s/ John F. Thero
Date: May 8, 2015						John F. Thero
						President and Chief Executive Officer (Principal Executive Officer)

						/s/ Michael J. Farrell
Date: May 8, 2015						Michael J. Farrell
						Vice President, Finance (Principal Financial Officer)

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not incorporated by reference into any filing of Amarin Corporation plc under the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.